Comparison of out-of-pocket costs and adherence between the two arms of the prospective, randomized abiraterone food effect trial

[1]  Arjun Gupta,et al.  Potential Cost Savings With Low-Dose Abiraterone in the United States , 2020, JCO global oncology.

[2]  I. Tannock,et al.  Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets , 2020, JCO global oncology.

[3]  M. Ratain,et al.  Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment. , 2019, JAMA oncology.

[4]  M. Ratain,et al.  Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Yongling Xiao,et al.  Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide. , 2017, American health & drug benefits.

[6]  David C. Miller,et al.  Early National Dissemination of Abiraterone and Enzalutamide for Advanced Prostate Cancer in Medicare Part D. , 2017, Journal of oncology practice.

[7]  A. Shields,et al.  Patient-reported preferences for oral versus intravenous administration for the treatment of cancer: a review of the literature , 2016, Patient preference and adherence.

[8]  E. Malangone-Monaco,et al.  Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis. , 2016, Clinical therapeutics.

[9]  J. Temel,et al.  A Systematic Review of Adherence to Oral Antineoplastic Therapies. , 2016, The oncologist.

[10]  F. Saad,et al.  Population Pharmacokinetic Analysis of Abiraterone in Chemotherapy-Naïve and Docetaxel-Treated Patients with Metastatic Castration-Resistant Prostate Cancer , 2014, Clinical Pharmacokinetics.

[11]  C. Kozma,et al.  Adherence Patterns for Abiraterone Acetate and Concomitant Prednisone Use in Patients with Prostate Cancer , 2014, Journal of managed care & specialty pharmacy.

[12]  G. Banna,et al.  Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer. , 2013, Clinical lung cancer.

[13]  T. Sagar,et al.  Nonadherence to Imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia , 2011, American journal of hematology.

[14]  L. Schwartzberg,et al.  Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions. , 2011, Journal of oncology practice.

[15]  B. Given,et al.  The challenges of oral agents as antineoplastic treatments. , 2011, Seminars in oncology nursing.

[16]  Dawn L. Hershman,et al.  Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer , 2011, Breast Cancer Research and Treatment.

[17]  Dawn L Hershman,et al.  Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  P. Kantoff,et al.  Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  L. Matza,et al.  Derivation and Validation of the ASK-12 Adherence Barrier Survey , 2009, The Annals of pharmacotherapy.

[20]  L. Staudt,et al.  Clinical Trials and Observations , 2007 .

[21]  T. Yap,et al.  Targeting CYP17: established and novel approaches in prostate cancer. , 2008, Current opinion in pharmacology.

[22]  H. Ward,et al.  Predictive Validity of a Medication Adherence Measure in an Outpatient Setting , 2008, Journal of clinical hypertension.

[23]  A. Lippman.  Adherence to medication. , 2005, The New England journal of medicine.

[24]  E. Winer,et al.  Adherence to therapy with oral antineoplastic agents. , 2002, Journal of the National Cancer Institute.

[25]  K. Calzone,et al.  Adherence to oral tamoxifen: a comparison of patient self-report, pill counts, and microelectronic monitoring. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  F. Dobbels,et al.  Measuring Patient-Reported Outcomes in Solid Organ Transplant Recipients , 2012, PharmacoEconomics.

[27]  Ann Partridge,et al.  Patient adherence and persistence with oral anticancer treatment , 2009, CA: a cancer journal for clinicians.

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[29]  J. Weinman,et al.  The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication , 1999 .